Further, reduced immunogenicity is achieved by using fully human natural ligand- or receptor-based CAR T. By repurposing high affinity ligand-receptor interactions to target overexpressed ligands [NKG2DL via NKG2D] (177) and receptors [BCMA & TACI via APRIL] (8) on cancers have been explored in the preclinical setting and in clinical trials (178). This evidence concerns the gene TNFRSF17 and cancer.